Complexing Receptor Pharmacology

Abstract:  The most well‐characterized subgroup of family B G protein–coupledreceptors (GPCRs) comprises receptors for peptide hormones, such as secretin, calcitonin (CT), glucagon, and vasoactive intestinal peptide (VIP). Recent data suggest that many of these receptors can interact with a novel family of GPCR accessory proteins termed receptor activity modifying proteins (RAMPs). RAMP interaction with receptors can lead to a variety of actions that include chaperoning of the receptor protein to the cell surface as is the case for the calcitonin receptor‐like receptor (CLR) and the generation of novel receptor phenotypes. RAMP heterodimerization with the CLR and related CT receptor is required for the formation of specific CT gene‐related peptide, adrenomedullin (AM) or amylin receptors. More recent work has revealed that the specific RAMP present in a heterodimer may modulate other functions such as receptor internalization and recycling and also the strength of activation of downstream signaling pathways. In this article we review our current state of knowledge of the consequence of RAMP interaction with family B GPCRs.

[1]  J. Henley,et al.  Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane , 2005, Journal of Cell Science.

[2]  P. Sexton,et al.  Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes , 2005, Molecular Pharmacology.

[3]  N. Aiyar,et al.  Novel Function for Receptor Activity-modifying Proteins (RAMPs) in Post-endocytic Receptor Trafficking*♦ , 2005, Journal of Biological Chemistry.

[4]  Michel Bouvier,et al.  Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. , 2005, Trends in pharmacological sciences.

[5]  D. Hay,et al.  The pharmacology of CGRP-responsive receptors in cultured and transfected cells , 2004, Peptides.

[6]  Patrick M Sexton,et al.  The receptor activity modifying protein family of G protein coupled receptor accessory proteins. , 2004, Seminars in cell & developmental biology.

[7]  P. Dougherty,et al.  Receptors and channels , 2004 .

[8]  P. Sexton,et al.  RAMPs: 5 years on, where to now? , 2003, Trends in pharmacological sciences.

[9]  K. Kitamura,et al.  Identification of the Human Receptor Activity-modifying Protein 1 Domains Responsible for Agonist Binding Specificity* , 2003, Journal of Biological Chemistry.

[10]  S. Wank,et al.  The Extracellular Domain of Receptor Activity-modifying Protein 1 Is Sufficient for Calcitonin Receptor-like Receptor Function* , 2003, The Journal of Biological Chemistry.

[11]  P. Sexton,et al.  Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.

[12]  S. Foord.  Receptor classification: post genome. , 2002, Current opinion in pharmacology.

[13]  Sarah Steiner,et al.  The transmembrane domain of receptor-activity-modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. , 2002, Biochemistry.

[14]  I. Dickerson,et al.  Receptor component protein (RCP): a member of a multi-protein complex required for G-protein-coupled signal transduction. , 2002, Biochemical Society transactions.

[15]  D. Firsov,et al.  Respective Roles of Calcitonin Receptor-like Receptor (CRLR) and Receptor Activity-modifying Proteins (RAMP) in Cell Surface Expression of CRLR/RAMP Heterodimeric Receptors* , 2002, The Journal of Biological Chemistry.

[16]  M. Bouvier,et al.  Agonist-promoted Internalization of a Ternary Complex between Calcitonin Receptor-like Receptor, Receptor Activity-modifying Protein 1 (RAMP1), and β-Arrestin* , 2001, The Journal of Biological Chemistry.

[17]  F. Marshall,et al.  Protein-Protein Interaction and Not Glycosylation Determines the Binding Selectivity of Heterodimers between the Calcitonin Receptor-like Receptor and the Receptor Activity-modifying Proteins* , 2001, The Journal of Biological Chemistry.

[18]  J. Holbrook,et al.  Bioinformatics and type II G-protein-coupled receptors. , 2001, Biochemical Society transactions.

[19]  R. McKinney,et al.  Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition. , 2000, The Biochemical journal.

[20]  T. Eto,et al.  Visualization of the Calcitonin Receptor-like Receptor and Its Receptor Activity-modifying Proteins during Internalization and Recycling* , 2000, The Journal of Biological Chemistry.

[21]  P. Sexton,et al.  Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. , 2000, The Journal of pharmacology and experimental therapeutics.

[22]  W. Born,et al.  Mammalian calcitonin receptor‐like receptor/receptor activity modifying protein complexes define calcitonin gene‐related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells , 2000, FEBS letters.

[23]  K. Rudolf,et al.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist , 2000, British journal of pharmacology.

[24]  P. Sexton,et al.  Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. , 2000, Biochemical and biophysical research communications.

[25]  M Morfis,et al.  Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. , 1999, Molecular pharmacology.

[26]  S. Foord,et al.  The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. , 1999, Molecular pharmacology.

[27]  Walter Born,et al.  An Amylin Receptor Is Revealed Following Co-Transfection of a Calcitonin Receptor with Receptor Activity Modifying Proteins-1 or -3. , 1999, Endocrinology.

[28]  F. Marshall,et al.  RAMPs: accessory proteins for seven transmembrane domain receptors. , 1999, Trends in pharmacological sciences.

[29]  D. Smith,et al.  Characterization of receptors for calcitonin gene‐related peptide and adrenomedullin on the guinea‐pig vas deferens , 1999, British journal of pharmacology.

[30]  D. Smith,et al.  Calcitonin gene-related peptide--a new concept in receptor-ligand specificity? , 1998, Trends in pharmacological sciences.

[31]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[32]  N. Aiyar,et al.  Molecular cloning and characterization of the porcine calcitonin gene-related peptide receptor. , 1998, Endocrinology.

[33]  B. Roos,et al.  Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Sexton,et al.  Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. , 1995, Molecular endocrinology.

[35]  D. Thompson,et al.  Cloning and characterization of an abundant subtype of the human calcitonin receptor. , 1994, Molecular pharmacology.

[36]  H. Lodish,et al.  Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. , 1992, The Journal of clinical investigation.

[37]  P. Sexton,et al.  GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.

[38]  K. Kitamura,et al.  Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. , 2004, Molecular pharmacology.